Short answer
PULSE BIOSCIENCES, INC. (PLSE) filed an 8-K current report with the SEC on April 9, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 7.01 (Regulation FD Disclosure). Liane R. Teplitsky appointed COO effective April 8, 2026, adding cardiovascular, electrophysiology, robotics, and digital-health commercialization experience.
PULSE BIOSCIENCES, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Liane R. Teplitsky appointed COO effective April 8, 2026, adding cardiovascular, electrophysiology, robotics, and digital-health commercialization experience
- Annual salary $525,000 with target bonus equal to 70% of base salary, aligning compensation with performance objectives
- 700,000-stock option grant at $19.06 exercise price, including 200,000 time-vesting shares and 500,000 performance-based shares
- Performance options tied to $2.0B, $3.0B, and $5.0B market capitalizations plus $100M, $200M, and $330M GAAP product revenue
- 200,000 restricted stock units tied to $100M, $200M, and $300M GAAP product revenue milestones, signaling aggressive commercialization targets
Item 7.01 · Regulation FD Disclosure
- Appointment of Ms. Teplitsky as Chief Operating Officer, signaling a leadership change in operations
- Press release attached as Exhibit 99.1 with additional background and appointment details
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other PULSE BIOSCIENCES, INC. 8-K filings
Get the next PLSE 8-K as it lands
Follow PLSE for push alerts, or ask the research agent what this filing means.